Nanobiotix (NBTX) Competitors $9.48 -0.22 (-2.22%) As of 02:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. EWTX, AUPH, CDTX, PAHC, ARDX, TWST, VERA, AVDL, COGT, and SNDXShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Edgewise Therapeutics (EWTX), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors Edgewise Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Phibro Animal Health Ardelyx Twist Bioscience Vera Therapeutics Avadel Pharmaceuticals Cogent Biosciences Syndax Pharmaceuticals Edgewise Therapeutics (NASDAQ:EWTX) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Do institutionals and insiders believe in EWTX or NBTX? 38.8% of Nanobiotix shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor EWTX or NBTX? In the previous week, Edgewise Therapeutics had 2 more articles in the media than Nanobiotix. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 3 mentions for Nanobiotix. Edgewise Therapeutics' average media sentiment score of 1.64 beat Nanobiotix's score of 0.55 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, EWTX or NBTX? Nanobiotix has higher revenue and earnings than Edgewise Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.99Nanobiotix$39.18M11.61-$73.73MN/AN/A Do analysts rate EWTX or NBTX? Edgewise Therapeutics presently has a consensus target price of $40.55, indicating a potential upside of 190.88%. Nanobiotix has a consensus target price of $8.00, indicating a potential downside of 15.66%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Edgewise Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is EWTX or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -30.65% -29.18% Nanobiotix N/A N/A N/A Which has more risk and volatility, EWTX or NBTX? Edgewise Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. SummaryEdgewise Therapeutics beats Nanobiotix on 7 of the 13 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$454.71M$2.83B$5.75B$10.27BDividend YieldN/A57.24%5.73%4.60%P/E RatioN/A23.3875.1826.37Price / Sales11.61532.07457.0688.69Price / CashN/A27.5625.8129.91Price / Book-6.285.4013.256.28Net Income-$73.73M$32.95M$3.29B$270.67M7 Day Performance8.90%0.13%0.72%2.79%1 Month Performance19.91%3.93%4.58%6.01%1 Year Performance91.62%-2.90%73.44%26.05% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix0.6322 of 5 stars$9.49-2.2%$8.00-15.7%+96.0%$454.71M$39.18M0.00100News CoverageUpcoming EarningsShort Interest ↑EWTXEdgewise Therapeutics2.6244 of 5 stars$14.88-4.4%$40.55+172.5%-24.4%$1.64BN/A-9.6060Positive NewsAUPHAurinia Pharmaceuticals2.9135 of 5 stars$12.30-0.8%$12.00-2.4%+81.2%$1.63B$235.13M28.61300News CoveragePositive NewsCDTXCidara Therapeutics3.1685 of 5 stars$62.15-1.6%$64.14+3.2%+449.6%$1.60B$1.27M-5.5890Positive NewsPAHCPhibro Animal Health4.4517 of 5 stars$39.43-0.1%$28.40-28.0%+80.2%$1.60B$1.30B33.422,475Analyst RevisionARDXArdelyx4.6217 of 5 stars$6.59+1.1%$11.70+77.5%+4.8%$1.57B$333.61M-28.6590Positive NewsTWSTTwist Bioscience3.9667 of 5 stars$26.25+1.9%$49.40+88.2%-46.1%$1.55B$312.97M-18.10990VERAVera Therapeutics2.745 of 5 stars$24.75+2.3%$63.00+154.5%-36.6%$1.54BN/A-6.9140Positive NewsAVDLAvadel Pharmaceuticals3.0866 of 5 stars$15.38-2.4%$20.86+35.6%+12.4%$1.53B$221.08M-512.6770COGTCogent Biosciences3.0485 of 5 stars$12.68-2.8%$20.00+57.7%+19.1%$1.49BN/A-7.1280Positive NewsSNDXSyndax Pharmaceuticals3.9171 of 5 stars$16.33-4.2%$38.89+138.1%-18.7%$1.47B$23.68M-4.20110 Related Companies and Tools Related Companies Edgewise Therapeutics Competitors Aurinia Pharmaceuticals Competitors Cidara Therapeutics Competitors Phibro Animal Health Competitors Ardelyx Competitors Twist Bioscience Competitors Vera Therapeutics Competitors Avadel Pharmaceuticals Competitors Cogent Biosciences Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBTX Stock Alerts